Lanadelumab: Solution for subcutaneous injection 300 mg in 2 mL; Takhzyro® Page last updated: 29 October 2021 Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1282KB) Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 142KB)